CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.
We need more specific therapies because current approaches result in many side-effects. Thats why we invented CATE, the first all-in-one
living cancer therapeutic with an integrated two-step safety mechanism.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
We are engineering E. coli Nissle to carry a MRI
contrast and a cytotoxic agent so it can deliver both components to tumor sites.
Project description
The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.
Design
We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.